Telerehabilitation Alzheimer's Disease Feasibility (TADF)

NAUnknownINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

February 16, 2022

Primary Completion Date

December 31, 2022

Study Completion Date

February 28, 2023

Conditions
Alzheimer DiseaseHealthy Aging
Interventions
DEVICE

BrightGo cognitive training

Training on the BrightGo experimental device in the home

DRUG

Standard of Care medication for early Alzheimer's Disease

Participant takes 10 mg of Aricept daily or wears an Exelon 9.5 mg patch and is stable on one of these medications that were prescribed for diagnostic of early Alzheimer's Disease

Trial Locations (2)

08901-2066

RECRUITING

Rutgers, The State University of New Jersey, New Brunswick

08902

RECRUITING

Bright Cloud Int'l Corp, North Brunswick

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

collaborator

Rutgers, The State University of New Jersey

OTHER

lead

Bright Cloud International Corp

INDUSTRY